Theralase Hits Key Enrollment Milestone in Phase II Bladder Cancer Trial

Theralase Technologies ( (TSE:TLT) ) has provided an announcement.

Theralase Technologies has completed enrollment and treatment of its targeted 90 patients in a multi-center Phase II registrational clinical study evaluating light-activated Ruvidar in patients with BCG-unresponsive non-muscle invasive bladder cancer carcinoma in situ, a population that faces limited options beyond radical cystectomy. Reaching this enrollment milestone is pivotal for the company’s regulatory strategy, as it provides the statistically meaningful dataset needed to support planned submissions to Health Canada and the FDA and could position Ruvidar as a bladder-sparing alternative in a high unmet-need segment of the bladder cancer market. Early clinical data indicate strong efficacy, durable responses and a favorable safety profile, with most patients achieving lasting benefit after a single treatment, and management signals that 2026 will be a transformative year as Theralase completes this study, prepares regulatory filings and initiates additional Phase I/II adaptive trials across multiple cancer types, potentially broadening its oncology pipeline and strengthening its competitive stance in photodynamic cancer therapies.

The most recent analyst rating on (TSE:TLT) stock is a Hold with a C$0.25 price target. To see the full list of analyst forecasts on Theralase Technologies stock, see the TSE:TLT Stock Forecast page.

Spark’s Take on TSE:TLT Stock

According to Spark, TipRanks’ AI Analyst, TSE:TLT is a Neutral.

The score is held down primarily by weak financial performance—very large losses versus a small and declining revenue base, ongoing cash burn, and substantial equity erosion. Technicals provide some support with strong recent momentum (price above major moving averages and positive MACD), but elevated RSI suggests the move may be stretched. Valuation remains unattractive due to negative earnings and no dividend yield.

To see Spark’s full report on TSE:TLT stock, click here.

More about Theralase Technologies

Theralase Technologies is a Toronto-based clinical-stage pharmaceutical company focused on developing light-, radiation-, sound- and drug-activated small molecule compounds and formulations aimed at safely and effectively destroying cancers, bacteria and viruses while minimizing damage to healthy tissue. Its lead technology, including the light-activated small molecule Ruvidar and the TLC-3200 medical laser system, is being advanced through multi-center clinical trials in North America, with an initial focus on high-risk non-muscle invasive bladder cancer and plans to expand into other solid tumor indications.

Average Trading Volume: 204,570

Technical Sentiment Signal: Buy

Current Market Cap: C$64.26M

Learn more about TLT stock on TipRanks’ Stock Analysis page.